Improving delivery of molecules to neurons in the brain
Enhancing Non-Viral Neuron-Specific Molecule Delivery Across Species in the CNS
['FUNDING_R01'] · UNIVERSITY OF TEXAS DALLAS · NIH-11168379
This study is looking at a special tiny protein called N1 that could help deliver medicine directly to brain cells, which might make treatments for neurological conditions work better and be easier to use.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS DALLAS (nih funded) |
| Locations | 1 site (RICHARDSON, UNITED STATES) |
| Trial ID | NIH-11168379 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the delivery of specific molecules to neurons in the central nervous system using a novel 15-amino-acid peptide called N1. The N1 peptide has shown the ability to selectively target neurons, which could improve the efficiency of delivering therapeutic agents for various neurological conditions. The research will explore how this peptide can transport different types of molecules into neurons across various species, aiming to overcome current limitations in non-viral delivery methods. By optimizing the stability and delivery capabilities of the N1 peptide, the study seeks to facilitate non-invasive brain delivery of therapeutic agents.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals with neurological conditions that could benefit from enhanced molecular delivery therapies.
Not a fit: Patients with conditions unrelated to neuronal delivery or those who do not require molecular therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for neurological disorders by improving how therapeutic molecules are delivered to neurons.
How similar studies have performed: While the approach of using peptides for targeted delivery is promising, this specific method is relatively novel and has not been extensively tested in human applications.
Where this research is happening
RICHARDSON, UNITED STATES
- UNIVERSITY OF TEXAS DALLAS — RICHARDSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: QIN, ZHENPENG — UNIVERSITY OF TEXAS DALLAS
- Study coordinator: QIN, ZHENPENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.